Independent Analyst Summary · For General Investors
Global market leader. Amplifon operates ~10,100 locations across 25 countries. Scale gives it pricing power, supplier leverage, and brand recognition that smaller rivals cannot match.
Structural tailwind intact. The hearing care market benefits from aging populations worldwide and rising awareness. Long-term demand is not in question — it's a when, not an if.
Cash generation is solid. Adjusted free cash flow of €174M was strong. The company has enough liquidity to fund its restructuring without needing emergency financing.
Restructuring ahead of schedule. The Fit4Growth program closed 160 loss-making clinics, cut 500 jobs, and reduced capital spending by €30M — all faster than planned. Implementation costs also came in lower (€25M vs €35M originally budgeted).
Digital push gaining traction. The new Amplifon App reached 25% penetration, and the branded product line expanded to 17 countries. These are early but real steps toward a higher-margin, direct-to-patient model.
| Region | % of Sales | Organic Growth | Margin | Verdict |
|---|---|---|---|---|
| EMEA | 65% | –0.6% | 26.6% | Mixed |
| Americas | 21% | +1.9% | 23.5% | Promising but costly |
| APAC | 14% | –0.3% | 24.9% | Struggling |
All margins are adjusted EBITDA. FX headwinds hit Americas (–6.3%) and APAC (–6.4%) hard.
Reported profit fell by 37%. The "adjusted" net profit of €159M looks manageable, but the actual reported figure — what accountants call the real number — was just €91M, down 37% from 2024. The gap between the two is growing, which means restructuring and one-off charges are becoming a regular feature, not an exception.
Zero organic growth for the full year. Organic growth — revenue from existing stores, excluding acquisitions and currency — was exactly 0.0% in 2025. The company calls the H2 recovery "significant," but a full year at zero is a clear sign the core business stalled.
UK exit comes with a hidden cost. Selling the UK business to a Demant rival is strategically sound, but it triggers an ~€18M accounting charge in Q1 2026 that will hurt next quarter's reported earnings. Investors should expect a messy Q1.
US insurance business is deteriorating. The managed care agreement termination (early 2026) removed ~1% of group revenue. The US insurance segment dragged on both Americas organic growth and margins all year — and there is no clear replacement strategy yet.
Debt is rising, not falling. Net debt increased from €962M to €1,046M during 2025, even after generating €174M of free cash flow. The company spent heavily on buybacks (€108M) and dividends (€65M) while also investing in acquisitions. Leverage moved in the wrong direction for the year.
The bull case: Fit4Growth delivers margin recovery toward 24–24.5%, organic growth returns to the 3–4% range as the market normalizes, and Miracle-Ear's direct network in the US begins generating returns on the significant investment made. The proposed €0.29/share dividend signals confidence from management.
The bear case: The US insurance segment continues to erode, Germany and APAC stay soft, currency headwinds persist as the euro stays strong, and the promised margin recovery is delayed into 2027 or beyond. The company also faces a €350M Eurobond maturity in 2027 that will need refinancing.
The bottom line for investors: Amplifon is not a company in crisis — it is a market leader going through a painful but manageable reset. The long-term thesis (aging populations, underpenetrated hearing care market, strong brand) remains intact. But 2025 revealed that the business is more cyclically and operationally sensitive than its premium valuation historically implied. Patient investors with a 3–5 year horizon may see opportunity; short-term investors should wait for evidence that organic growth and margins are genuinely recovering before buying in.